Skip to main content
Top
Published in: BMC Infectious Diseases 1/2024

Open Access 01-12-2024 | Hepatitis C | Research

Unraveling IL-17 and IL-22 role in occult hepatitis C versus chronic hepatitis C virus infection

Authors: Sherif Elbaz, Nasser Mousa, Alaa Elmetwalli, Ahmed Abdel-Razik, Mohamed Salah, Amr ElHammady, Mostafa Abdelsalam, Eman Abdelkader, Niveen El-wakeel, Waleed Eldars, Ola El-Emam, Ahmed Elbeltagy, Mohamed Shaheen, Hossam El-Zamek, Eman Mousa, Ahmed Deiab, Ayman Elgamal, Alaa Habib

Published in: BMC Infectious Diseases | Issue 1/2024

Login to get access

Abstract

Background

Cytokines play a crucial role in regulating the function of the immune system by controlling the production, differentiation, and activity of immune cells. Occult hepatitis C virus (OHCV) infection can lead to liver damage, including cirrhosis and hepatocellular carcinoma. This study investigates the immunopathogenic impact of the cytokines IL-17 and IL-22 in OHCV infection compared to chronic hepatitis C (CHC) infection.

Methods

We studied three groups of patients: 35 with OHCV, 100 untreated patients with CHC, and 30 healthy control subjects. All subjects underwent physical examination and biochemical testing. We used the sandwich enzyme-linked immunosorbent assay method to measure serum IL-17 and IL-22 levels in all groups.

Results

Compared to the occult and control groups, the CHC group had significantly higher serum IL-17 levels (p < 0.001). The occult group also had higher serum IL-17 levels compared to the control group (p < 0.0001). There were no significant differences in IL-22 levels across the research groups. In the OHCV group, individuals with moderate inflammation (A2-A3) had significantly higher serum IL-17 levels than those with minimal inflammation (A0-A1), while in the CHC group, this difference was not statistically significant (p = 0.601). Neither the occult nor the CHC groups showed a correlation between serum IL-22 and inflammatory activity. There was no significant correlation between the levels of IL-17 or IL-22 and the stage of fibrosis/cirrhosis in either group. ROC curves were calculated for serum IL-17 and IL-22 levels and occult HCV infection, with cut-off values set at ≤ 32.1 pg/ml and < 14.3 pg/ml for IL-17 and IL-22, respectively. The AUROC (95%CI) was significantly higher for IL-17 than IL-22 (0.829 (0.732–0.902) vs. 0.504 (0.393–0.614), p < 0.001), suggesting that IL-17 has a stronger correlation with infection risk than IL-22.

Conclusion

This study suggests that IL-17 may be involved in the immunopathogenesis of OHCV infection, especially in patients with moderate inflammation.
Literature
1.
go back to reference Polaris Observatory HCV, Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–76.CrossRef Polaris Observatory HCV, Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–76.CrossRef
2.
go back to reference European Union HCV, Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:325–36.CrossRef European Union HCV, Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:325–36.CrossRef
3.
go back to reference BM, D. A new twist to a chronic HCV infection: occult hepatitis C. Gastroenterol Res Pract. 2015;2015:579147. BM, D. A new twist to a chronic HCV infection: occult hepatitis C. Gastroenterol Res Pract. 2015;2015:579147.
4.
go back to reference Hedayati-Moghaddam MR, Soltanian H, Ahmadi-Ghezeldasht S. Occult Hepatitis C virus infection in the Middle East and Eastern Mediterranean countries: a systematic review and meta-analysis. World J Hepatol. 2021;13(2):242–60.CrossRefPubMedPubMedCentral Hedayati-Moghaddam MR, Soltanian H, Ahmadi-Ghezeldasht S. Occult Hepatitis C virus infection in the Middle East and Eastern Mediterranean countries: a systematic review and meta-analysis. World J Hepatol. 2021;13(2):242–60.CrossRefPubMedPubMedCentral
5.
go back to reference Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol. 2004;78(11):5867–74.CrossRefPubMedPubMedCentral Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol. 2004;78(11):5867–74.CrossRefPubMedPubMedCentral
6.
go back to reference Castillo I, Pardo M, Bartolomé J, et al. Occult Hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis. 2004;189(1):7–14.CrossRefPubMed Castillo I, Pardo M, Bartolomé J, et al. Occult Hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis. 2004;189(1):7–14.CrossRefPubMed
7.
go back to reference Ribeiro CRA, de Almeida NAA, Martinelli KG, et al. Cytokine profile during occult hepatitis B virus infection in chronic hepatitis C patients. Virol J. 2021;18(1):15.CrossRefPubMedPubMedCentral Ribeiro CRA, de Almeida NAA, Martinelli KG, et al. Cytokine profile during occult hepatitis B virus infection in chronic hepatitis C patients. Virol J. 2021;18(1):15.CrossRefPubMedPubMedCentral
9.
go back to reference Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Long-term virological follow up of patients with occult hepatitis C virus infection. Liver Int. 2011;31:1519–24.CrossRefPubMed Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Long-term virological follow up of patients with occult hepatitis C virus infection. Liver Int. 2011;31:1519–24.CrossRefPubMed
10.
go back to reference Irshad M, Mankotia DS, Irshad K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol. 2013;19(44):7896–909.CrossRefPubMedPubMedCentral Irshad M, Mankotia DS, Irshad K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol. 2013;19(44):7896–909.CrossRefPubMedPubMedCentral
11.
go back to reference Mousa N, Abdel-Aziz M, Farag R, Soliman R, abed S, Hasson A. Recent trends in chronic hepatitis C virus treatment. Med J Viral Hepatitis March. 2018;22(2):1–6. Mousa N, Abdel-Aziz M, Farag R, Soliman R, abed S, Hasson A. Recent trends in chronic hepatitis C virus treatment. Med J Viral Hepatitis March. 2018;22(2):1–6.
12.
go back to reference Hao C, Wang J, Kang W et al. Kinetics of Th17 cytokines during telbivudine therapy in patients with chronic Hepatitis B. viral immunology. October 2013:336–42. Hao C, Wang J, Kang W et al. Kinetics of Th17 cytokines during telbivudine therapy in patients with chronic Hepatitis B. viral immunology. October 2013:336–42.
13.
14.
go back to reference Mousa N, Ahmed A, Ilham T, sheta T, Hassan R, Ahmed D, et al. The role of interleukin-2 and interleukin-4 in disease progression in patients with schistosomiasis combined with chronic viral hepatitis C and chronic viral hepatitis B. Med J Viral Hepatitis April. 2019;3(2):57–64. Mousa N, Ahmed A, Ilham T, sheta T, Hassan R, Ahmed D, et al. The role of interleukin-2 and interleukin-4 in disease progression in patients with schistosomiasis combined with chronic viral hepatitis C and chronic viral hepatitis B. Med J Viral Hepatitis April. 2019;3(2):57–64.
15.
go back to reference Hofmann SR, Ettinger R, Zhou YJ, Gadina M, Lipsky P, Siegel R, et al. Cytokines and their role in lymphoid development, differentiation and homeostasis. Curr Opin Allergy Clin Immunol. 2002;2:495–506.CrossRefPubMed Hofmann SR, Ettinger R, Zhou YJ, Gadina M, Lipsky P, Siegel R, et al. Cytokines and their role in lymphoid development, differentiation and homeostasis. Curr Opin Allergy Clin Immunol. 2002;2:495–506.CrossRefPubMed
16.
go back to reference Kim BS, Ho UW, Kang HS. Th17 cells enhance viral persistance and inhibit T cell cytotoxicity in a model of chronic virus infection. J Exp Med. 2009;206:313–28.CrossRefPubMedPubMedCentral Kim BS, Ho UW, Kang HS. Th17 cells enhance viral persistance and inhibit T cell cytotoxicity in a model of chronic virus infection. J Exp Med. 2009;206:313–28.CrossRefPubMedPubMedCentral
17.
go back to reference Cabral MS, Santos TPS, Santos PL, Schinoni MI, Oliveira IS, Pereira AB, Atta AM, Sousa-Atta MLB. Immune response of Th17-associated cytokines by peripheral blood mononuclear cells from patients with chronic hepatitis C virus infection. Cytokine. 2018;102:200–5.CrossRefPubMed Cabral MS, Santos TPS, Santos PL, Schinoni MI, Oliveira IS, Pereira AB, Atta AM, Sousa-Atta MLB. Immune response of Th17-associated cytokines by peripheral blood mononuclear cells from patients with chronic hepatitis C virus infection. Cytokine. 2018;102:200–5.CrossRefPubMed
18.
go back to reference Park H, Li Z, Yang X, et al. A distinct lineage of CD4 T cells regulates tissue inflammationby producing interleukin 17. Nat Immunol. 2005;6:1133–41.CrossRefPubMedPubMedCentral Park H, Li Z, Yang X, et al. A distinct lineage of CD4 T cells regulates tissue inflammationby producing interleukin 17. Nat Immunol. 2005;6:1133–41.CrossRefPubMedPubMedCentral
19.
20.
go back to reference Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity. 2004;21:241–54.CrossRefPubMed Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity. 2004;21:241–54.CrossRefPubMed
21.
go back to reference Fabre T, Molina MF, Soucy G, Goulet JP, Willems B, Villeneuve JP, Bilodeau M, Shoukry NH. Type 3 cytokines IL-17A and IL-22 drive TGF-β-dependent liver fibrosis. Sci Immunol. 2018;3(28):eaar7754.CrossRefPubMed Fabre T, Molina MF, Soucy G, Goulet JP, Willems B, Villeneuve JP, Bilodeau M, Shoukry NH. Type 3 cytokines IL-17A and IL-22 drive TGF-β-dependent liver fibrosis. Sci Immunol. 2018;3(28):eaar7754.CrossRefPubMed
22.
go back to reference Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–93.CrossRefPubMed Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–93.CrossRefPubMed
23.
go back to reference Mousa N, Eldars W, Eldegla H, et al. Cytokine profiles and hepatic injury in occult hepatitis C versus chronic hepatitis C virus infection. Int J Immunopathol Pharmacol. 2014;27(1):87–96. Jan-Mar.CrossRefPubMed Mousa N, Eldars W, Eldegla H, et al. Cytokine profiles and hepatic injury in occult hepatitis C versus chronic hepatitis C virus infection. Int J Immunopathol Pharmacol. 2014;27(1):87–96. Jan-Mar.CrossRefPubMed
24.
go back to reference McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol. 1994;32:884–92.CrossRefPubMedPubMedCentral McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol. 1994;32:884–92.CrossRefPubMedPubMedCentral
25.
go back to reference Mbaga DS, Kenmoe S, Bikoï JN, et al. Global prevalence of occult hepatitis C virus: a systematic review and meta-analysis. World J Methodol. 2022;12(3):179–90.CrossRefPubMedPubMedCentral Mbaga DS, Kenmoe S, Bikoï JN, et al. Global prevalence of occult hepatitis C virus: a systematic review and meta-analysis. World J Methodol. 2022;12(3):179–90.CrossRefPubMedPubMedCentral
26.
go back to reference Veldhoen M, Stockinger B. TGFbeta1, a Jack of all trades: the link with pro-inflammatory IL-17-producing T cells. Trends Immunol. 2006;27(8):358–61.CrossRefPubMed Veldhoen M, Stockinger B. TGFbeta1, a Jack of all trades: the link with pro-inflammatory IL-17-producing T cells. Trends Immunol. 2006;27(8):358–61.CrossRefPubMed
27.
go back to reference Bălănescu P, Lădaru A, Voiosu T, Nicolau A, Ene M, Bălănescu E. Th17 and IL- 17 immunity in chronic hepatitis C infection. Rom J Intern Med. 2012;50(1):13–8. Jan-Mar.PubMed Bălănescu P, Lădaru A, Voiosu T, Nicolau A, Ene M, Bălănescu E. Th17 and IL- 17 immunity in chronic hepatitis C infection. Rom J Intern Med. 2012;50(1):13–8. Jan-Mar.PubMed
28.
go back to reference Chang Q, Wang YK, Zhao Q, Wang CZ, Hu YZ, Wu BY. Th17 cells are increased with severity of liver inflammation in patients with chronic hepatitis C. J Gastroenterol Hepatol. 2012;27:273–8.CrossRefPubMed Chang Q, Wang YK, Zhao Q, Wang CZ, Hu YZ, Wu BY. Th17 cells are increased with severity of liver inflammation in patients with chronic hepatitis C. J Gastroenterol Hepatol. 2012;27:273–8.CrossRefPubMed
29.
go back to reference Dambacher J, Beigel F, Zitzmann K, et al. The role of interleukin-22 in hepatitis C virus infection. Cytokine. 2008;41(3):209–16.CrossRefPubMed Dambacher J, Beigel F, Zitzmann K, et al. The role of interleukin-22 in hepatitis C virus infection. Cytokine. 2008;41(3):209–16.CrossRefPubMed
30.
go back to reference Macek Jilkova Z, Afzal S, Marche H, Decaens T, Sturm N, Jouvin-Marche E, Huard B, Marche. PN Progression of fibrosis in patients with chronic viral hepatitis is associated with IL-17(+) neutrophils. Liver Int. 2016;36:1116–24.CrossRefPubMed Macek Jilkova Z, Afzal S, Marche H, Decaens T, Sturm N, Jouvin-Marche E, Huard B, Marche. PN Progression of fibrosis in patients with chronic viral hepatitis is associated with IL-17(+) neutrophils. Liver Int. 2016;36:1116–24.CrossRefPubMed
31.
go back to reference Rios DA, Casciato PC, Caldirola MS, Gaillard MI, Giadans C, Ameigeiras B, De Matteo EN, Preciado MV, Valva P. Chronic Hepatitis C Pathogenesis: Immune Response in the Liver Microenvironment and Peripheral Compartment. Front Cell Infect Microbiol. 2021;11:712105.CrossRefPubMedPubMedCentral Rios DA, Casciato PC, Caldirola MS, Gaillard MI, Giadans C, Ameigeiras B, De Matteo EN, Preciado MV, Valva P. Chronic Hepatitis C Pathogenesis: Immune Response in the Liver Microenvironment and Peripheral Compartment. Front Cell Infect Microbiol. 2021;11:712105.CrossRefPubMedPubMedCentral
32.
go back to reference Paquissi FC. Immunity and fibrogenesis: the role of Th17/IL-17 Axis in HBV and HCV-induced chronic Hepatitis and Progression to Cirrhosis. Front Immunol. 2017;8:1195.CrossRefPubMedPubMedCentral Paquissi FC. Immunity and fibrogenesis: the role of Th17/IL-17 Axis in HBV and HCV-induced chronic Hepatitis and Progression to Cirrhosis. Front Immunol. 2017;8:1195.CrossRefPubMedPubMedCentral
33.
go back to reference Sousa GM, Oliveira IS, Andrade LJ, Sousa-Atta ML, Parana R, Atta AM. Serum levels of Th17 associated cytokines in chronic hepatitis C virus infection. Cytokine. Oct; 2012;60(1):138–42.CrossRefPubMed Sousa GM, Oliveira IS, Andrade LJ, Sousa-Atta ML, Parana R, Atta AM. Serum levels of Th17 associated cytokines in chronic hepatitis C virus infection. Cytokine. Oct; 2012;60(1):138–42.CrossRefPubMed
34.
go back to reference Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity. 2007;27(4):647–59.CrossRefPubMedPubMedCentral Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity. 2007;27(4):647–59.CrossRefPubMedPubMedCentral
35.
go back to reference Foster RG, Golden-Mason L, Rutebemberwa A, et al. Interleukin (IL)-17/IL-22-Producing T cells enriched within the liver of patients with chronic Hepatitis C viral (HCV) infection. Dig Dis Sci. 2012;57:381–9.CrossRefPubMed Foster RG, Golden-Mason L, Rutebemberwa A, et al. Interleukin (IL)-17/IL-22-Producing T cells enriched within the liver of patients with chronic Hepatitis C viral (HCV) infection. Dig Dis Sci. 2012;57:381–9.CrossRefPubMed
36.
go back to reference Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, Cong M, et al. Interleukin-17 signaling in inflammatory, kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology. 2012;143:765–76.CrossRefPubMed Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, Cong M, et al. Interleukin-17 signaling in inflammatory, kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology. 2012;143:765–76.CrossRefPubMed
37.
go back to reference Vujovic A, Isakovic AM, Misirlic-Dencic S, Juloski J, Mirkovic M, Cirkovic A, Djelic M, Milošević I. IL-23/IL-17 Axis in Chronic Hepatitis C and non-alcoholic steatohepatitis—new insight into immunohepatotoxicity of different Chronic Liver diseases. Int J Mol Sci. 2023;24:12483.CrossRefPubMedPubMedCentral Vujovic A, Isakovic AM, Misirlic-Dencic S, Juloski J, Mirkovic M, Cirkovic A, Djelic M, Milošević I. IL-23/IL-17 Axis in Chronic Hepatitis C and non-alcoholic steatohepatitis—new insight into immunohepatotoxicity of different Chronic Liver diseases. Int J Mol Sci. 2023;24:12483.CrossRefPubMedPubMedCentral
Metadata
Title
Unraveling IL-17 and IL-22 role in occult hepatitis C versus chronic hepatitis C virus infection
Authors
Sherif Elbaz
Nasser Mousa
Alaa Elmetwalli
Ahmed Abdel-Razik
Mohamed Salah
Amr ElHammady
Mostafa Abdelsalam
Eman Abdelkader
Niveen El-wakeel
Waleed Eldars
Ola El-Emam
Ahmed Elbeltagy
Mohamed Shaheen
Hossam El-Zamek
Eman Mousa
Ahmed Deiab
Ayman Elgamal
Alaa Habib
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2024
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-024-09032-6

Other articles of this Issue 1/2024

BMC Infectious Diseases 1/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.